Safety Notices. Except as would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there have been no material recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other written notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products (collectively, “Safety Notices”). To the Company’s knowledge, there are no material written complaints with respect to the Company Products that are currently unresolved. To the Company’s knowledge, there are no facts that would be reasonably likely to result in (i) a material Safety Notice with respect to the Company Products, (ii) a material change in labeling of any the Company Products, or (iii) a material termination or suspension of marketing or testing of any of the Company Products.
Appears in 9 contracts
Samples: Underwriting Agreement (Option Care Health, Inc.), Option Care (Option Care Health, Inc.), Underwriting Agreement (Option Care Health, Inc.)
Safety Notices. Except as would not, whether individually or described in the aggregate, reasonably be expected to have a Material Adverse Effect, Registration Statement and the Prospectus: (A) there have been no material recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other written notice notices of action relating to an alleged lack of safety, efficacy, efficacy or regulatory compliance of the Company Products products (collectively, “Safety Notices”). To ) that remain unresolved or open; and (B) to the Company’s knowledge, there are no material written complaints with respect to the Company Products products that are currently unresolved. To the Company’s knowledge, there are no facts that would be reasonably likely to result in in: (iA) a material Safety Notice with respect to the Company Products, products; (iiB) a material change in labeling of any of the Company Products, products; or (iiiC) a material termination or suspension of marketing or testing of any of the Company Productsproducts.
Appears in 1 contract
Samples: Travere Therapeutics, Inc.
Safety Notices. Except as would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, there have been no material recalls, field notifications, field corrections, market withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other written notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Company Products (collectively, “Safety Notices”). To the Company’s and the Guarantors’ knowledge, there are no material written complaints with respect to the Company Products that are currently unresolved. To the Company’s and the Guarantors’ knowledge, there are no facts that would be reasonably likely to result in (i) a material Safety Notice with respect to the Company Products, (ii) a material change in labeling of any the Company Products, or (iii) a material termination or suspension of marketing or testing of any of the Company Products.
Appears in 1 contract